Aurion Biotech Launches Vyznova® (neltependocel) in Japan for the Treatment of Bullous Keratopathy of the Cornea

Contributed by: Business Wire

Logo

Images

Allogeneic Cell Therapy to Treat Corneal Endothelial Disease (Graphic: Business Wire)

Business Wire embedded0

Tags

Health

Surgery

Genetics

Pharmaceutical

Optical

Biotechnology

Launches Vyznova in Japan

More Like This

Celltrion Expands Biosimilar Portfolio in the European Union Following European Commission Approval of Two Biosimilars

Celltrion Receives Positive CHMP Opinion for Three Biosimilars in the European Union

Avanzanite Bioscience Reports European Commission's Authorisation of Orphan Medicinal Product AKANTIOR®

In 2008, GN Corp initiated research with NCRM, Chennai, Tamil Nadu, India on restoring corneal blindness using buccal tissue epithelial cells. An out of the box idea of Dr. Suryaprakash, Urologist from Hyderabad, India in 2012 to apply buccal (oral) mucosal cells to repair stricture-inflicted male urethra, led to a clinical study, which he presented in NCRM NICHE 2017 in Tokyo, kickstarting a collaboration with Dr. Akio Horiguchi, National Defence Medical College, Japan, as they met in EAU in 2018 (Top right picture). Upon confirming successful cell engraftment in urethral stricture pre-clinical models taking help from the Dept. of Medical Engineering of NDMC between 2018~2023, (Bottom, right picture), now in 2025, clinical application has been initiated in Edogawa Hospital, Tokyo. Main picture: BEES-HAUS team after the first clinical transplant in Edogawa Hospital, Tokyo; Dr.Horiguchi (Centre) with Dr.Shojiro Katoh (President, Edogawa Hospital) standing left to him.

Cell therapy for male urethral stricture: BEES-HAUS clinical application in Edogawa Hospital Japan, reports Dr. Akio Horiguchi in IMORU.

Novaliq Receives Positive CHMP Opinion for Vevizye® in Dry Eye Disease (Graphic: Business Wire)

Novaliq Receives Positive CHMP Opinion for Vevizye® in Dry Eye Disease

Kenai Therapeutics Announces $82 Million Series A Financing to Advance Next Generation Allogeneic Cell Therapies for Neurological Diseases

OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board

PR Newswire associated0

S&E bio Receives Korea's First Approval for Exosome-Based Therapy Clinical Trial